Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
Redefining Recurrence Risk in HR+/HER2− Early Breast Cancer: Applying Evolving CDK4/6 Inhibitor Evidence to Adjuvant Treatment Decisions
Javier Cortes, MD, PhD
Stephanie Graff, MD
From Eligibility to Treatment Planning: Translating ESMO Data Into Adjuvant CDK4/6 Decision-Making
Can PCE Induction Improve Outcomes in Advanced HNSCC?
Surgery vs Definitive RT for Pharyngeal and Laryngeal SCC
Treatment Order and Survival in Recurrent or Metastatic Head and Neck Cancer
Ryan Quigley
The Search for Radioresistance Biomarkers in Head and Neck Squamous Cell Carcinoma
Heath Skinner, MD, PhD
How Cancer Worry Influences Smoking Cessation
Hermine Poghosyan, PhD
KRAS G12C Biology: Why Is This Mutation Different?
Timothy F. Burns, MD, PhD
CDK4/6 in EBC After ESMO: From Early Signals to Greater Clarity
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
Gerard A. Silvestri MD, MS
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
Key Drivers of Radioresistance in Head and Neck Squamous Cell Carcinoma
CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
Alexandria May, PharmD, BCPS
Tara Graff, DO, MS
Making the Most of Biomarker Testing in NSCLC
Steve Jackson, PharmD
Angel Qin, MD
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Test Before You Treat: Biomarkers That Shape CLL Care
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
Biomarker Testing After Progression in HR+/HER2- mBC
Adam Brufsky, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.